Anas Younes, MD

Dr. Younes Discusses the Future of CAR T-Cell Therapy

April 10th 2018

Anas Younes, MD, chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the future of chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.

Dr. Younes Discusses Ibrutinib Plus Nivolumab in NHL

February 27th 2018

Anas Younes, MD, Chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the combination of ibrutinib (Imbruvica) plus nivolumab (Opdivo) in non-Hodgkin lymphoma.

Dr. Younes on Atezolizumab, Obinutuzumab, and Bendamustine in Follicular Lymphoma

December 11th 2017

Anas Younes, MD, Chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the interim analysis of a study exploring the safety and efficacy of atezolizumab (Tecentriq) in combination with obinutuzumab (Gazya) and bendamustine in patients with previously untreated follicular lymphoma.

Dr. Younes on 2016 ASH Highlights in Mantle Cell Lymphoma

December 15th 2016

Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer, discusses highlights from the 2016 ASH Annual Meeting focused on the area of mantle cell lymphoma (MCL).

Dr. Younes Discusses FDA Approval of Nivolumab in Hodgkin Lymphoma

July 25th 2016

Anas Younes, MD, chief of the Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the impact of the FDA approval of nivolumab (Opdivo) for the treatment of patients with classical Hodgkin lymphoma.

Dr. Anas Younes on Impact of CheckMate 205 in Classical Hodgkin Lymphoma

June 12th 2016

Dr. Younes on Brentuximab Plus AVD vs ABVD in Classical Hodgkin Lymphoma

August 28th 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the ongoing Echelon-1 study in classical Hodgkin lymphoma.

Dr. Younes on R-CHOP in Combination with Ibrutinib in DLBCL

June 3rd 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses a phase III study of ibrutinib in combination R-CHOP in patients with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma.

Dr. Younes Discusses the Future of Treating Lymphoid Malignancies

May 6th 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the future of treating lymphoid malignancies.

Dr. Younes on the Implications of Ibrutinib's Approval for MCL

April 4th 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the implications of ibrutinib's approval for patients with mantle cell lymphoma (MCL).

Dr. Anas Younes Discusses IPI-145 and ABT-199

March 19th 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the clinical value of IPI-145 and ABT-199 as treatment options for lymphoid malignancies.

Lymphoma Research Focuses on Targeting Genetic Drivers

December 3rd 2013

During the past three decades, our treatment approach to lymphoma has been based on the underlying histological and clinical features of the disease.